Company Overview - CRISPR Therapeutics has been operational for approximately 11 years, with the CRISPR platform being developed over the past 13 years, leading to the commercialization of CASGEVY for sickle cell disease and thalassemia [2] - The company is now focusing on diversifying its portfolio beyond its initial product, with significant developments in cardiovascular medicine [2] Key Focus Areas - The company is building two major pillars, one of which is in cardiovascular medicine, targeting liver editing using a single injection of an LNP encapsulated CRISPR/Cas9 system [3] - Recent data for the ANGPTL3 target showed an impressive nearly 80% reduction in both LDL and triglycerides from a single injection, exceeding the company's expectations [3] - Additional targets in cardiovascular medicine include LPA and AGT, indicating ongoing research and development efforts in this area [3]